BioAtla (BCAB) Revenue (2020 - 2026)

BioAtla (BCAB) posted quarterly Revenue of $2.0 million for Q4 2025, down 81.82% quarter-over-quarter from $11.0 million in Q3 2024.

BioAtla (BCAB) Revenue (2020 - 2026) Analysis & Trends

BioAtla's Revenue history runs 4 years deep, the most recent figure standing at $2.0 million for Q4 2025.

In Q4 2025, Revenue changed N/A year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $13.0 million (up 18.18% YoY), while the FY2025 annual figure was $2.0 million, down 81.82% from the prior year.
Revenue for Q4 2025 stood at $2.0 million, down from $11.0 million in the prior quarter.
The five-year high for Revenue was $11.0 million in Q3 2024, with the low at $250000.0 in Q2 2021.
The 3-year median for Revenue is $2.0 million (2025), against an average of $4.4 million.
Peak annual rise in Revenue reached 31.58% in 2021, while the deepest fall reached 31.58% in 2021.
BioAtla's Revenue stood at $250000.0 in 2021, then soared by 4300.0% to $11.0 million in 2024, then slumped by 81.82% to $2.0 million in 2025.
Business Quant data shows BCAB's Revenue at $2.0 million in Q4 2025, $11.0 million in Q3 2024, and $250000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	BioAtla	5.28 Mn	5.28 Mn	-	6.50 Mn

Download Data